On August 6, 2021, a group of 12 authors led by Prof. Dr. Tran Huu Dang was honored to be granted a patent by The Intellectual Property Department of the Ministry of Science and Technology according to Decision 12883w/QD-SHTT on The process of preparing granules for the treatment of benign prostatic hypertrophy.
This is a State-level scientific project under the Protocol. The research is extremely useful and practical, making it easier and more effective to treat patients with benign prostatic hypertrophy. After the new technique is implemented, patients will be able to easily access and consume the medicine at low a price. It is also the first patent of the University of Medicine and Pharmacy, Hue University.
This is a scientific study that was conducted at Hue University of Medicine and Pharmacy from 2012 to 2018 involves a team of 12 authors, including:
- Prof. Dr. Tran Huu Dang
- Assoc. Prof. Dr. Nguyen Thi Tan
- Prof. Dr. Tran Van Huy
- Assoc. Prof. Dr. Le Dinh Khanh
- Assoc. Prof. Dr. Tran Dinh Binh
- Assoc. Prof. Dr. Hoang Minh Chung
- Assoc. Prof. Dr. Vu Thi Ngoc Thanh
- Assoc. Prof. Dr. Hoang Van Tung
- MSc.Second Level Specialist. Pham Thi Xuan Mai
- Prof. Dr. Nguyen Thi Hoai
- MSc. Le Thi Minh Nguyet
- Second Level Specialist. Le Nhan
The patent on The process of preparing granules for the treatment of benign prostatic hypertrophy is the result of the cooperation research project under the Protocol with China, titled “Study on the preparation and evaluation of the effects of Prostate detoxification medicine used to treat benign prostatic hypertrophy” chaired by Prof. Dr. Tran Huu Dang and Assoc.Prof. Dr. Nguyen Thi Tan is the general secretary of the project. The project was joined by researchers of Hue University of Medicine and Pharmacy, Hanoi Medical University, and Department of Health Protection for Officials of Thua Thien Hue Province, including Prof. Dr. Tran Huu Dang, Assoc. Prof. Dr. Nguyen Thi Tan, Prof. Dr. Tran Van Huy, Assoc.Prof. Dr. Le Dinh Khanh, Assoc.Prof. Dr. Tran Dinh Binh, Assoc.Prof. Dr. Hoang Minh Chung, Assoc.Prof. Dr. Vu Thi Ngoc Thanh, Assoc.Prof. Dr. Hoang Van Tung, MSc.Second Level Specialist Pham Thi Xuan Mai, Prof. Dr. Nguyen Thi Hoai, MSc. Le Thi Minh Nguyet, Second Level Specialist Le Nhan.
On December 4, 2018, the research team received a Decision to accept the satisfactory application, thanks to the active support of the Department of Science, Technology, and International Cooperation, Hue University of Medicine and Pharmacy, and the Department of Science and Technology of Hue University, as well as the efforts of the research team and the constant encouragement of Prof. Dr. Nguyen Vu Quoc Huy.
In January 2020, subscription content for the patent of the research team was published in the IP Gazette No. 382, compilation A, Vol 1 (01.2020). And until now, after almost 3 years from the date of filing for the first time, the team has received a Patent dated August 8, 2021 (the actual reception date is September 24, 2021).
The useful solution was related to the pharmaceutical sector, specifically referring to the preparation process of granules for the treatment of benign prostatic hypertrophy, and the granules are obtained from this process. The obtained granules following the useful solution are created on the basis of the remedy of Prostate detoxification phytomedicine, which is derived from the ancient remedy Tu Dieu Hoan, including 4 herbs: Thương truật (Rhizoma Atractylodis), Hoàng bá (Cortex Phellodendri amurensis), Ý dĩ (Semen Coicis), Ngưu tất (Radix Achyranthis bidentatae).The additional herbs are Đan sâm (Radix Salviae miltiorrhizae), Vương bất lưu hành (trâu cổ) (Fructus Fici pumilae), Bạch hoa xà thiệt thảo (Herba Oldenlandiae diffusae), Hồng hoa (Flos Carthami tinctorii).
The process of preparing granules according to the utility solution using contemporary preparation technology results in a high-quality product, decreasing the amount of medicine patients must take on a daily basis (9g/dose against 60g/dose for a known cure for Prostate detoxification).
The product has a therapeutic influence on patients with benign prostatic hypertrophy and can be used in patients with benign prostatic hypertrophy and diabetes for the use of lactose in this preparation. The product does not cause unwanted clinical effects.
